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OR the last several years, transmission computerized tomography (CT) has been the study of choice for the diagnosis and follow-up monitoring of cerebral giomas. There is general agreement that CT is ideal for identifying the tumor, its location, and its size. Various CT features are used to characterize these cerebral tumors and to separate the more malignant from the relatively benign types. The presence of enhancement of the tumor parenchyma after intravenous injection of contrast material has proven to be the most useful diagnostic finding, since the majority of high-grade supratentorial astrocytomas (III and IV) demonstrate contrast enhancement, whereas low-grade astrocytomas (I and II) usually show little or no change in the radiographic density of the tumor after contrast infusion. 4 Considering high-grade tumors separately, the differentiation between Grade III and IV astrocytomas is not always possible, even histologically, because of variability in tissue sampling. In addition, the biological behavior of these generally aggressive tumors varies from patient to patient, and these differences cannot be appreciated either on angiograms or on CT scans ( Fig. 1 left pair) . These difficulties are even greater in the posttreatment period, since increasing enhancement in the pathological region as seen on CT may be caused by surgical manipulation or by radiation damage. 25 Conversely, if the enhanced area is diminishing, it is equally difficult to establish whether the tumor size is decreasing or whether steroid treatment has partially repaired the blood-brain barrier, thus preventing the detection of the entire tumor. 6,2~ It is therefore obvious that conventional neuroradiological modalities (CT and angiography) have limited value for the assessment of the aggressiveness of these tumors.
The present study has been undertaken to determine whether positron emission tomography (PET) with fluorine-18 ('SF)-2-deoxyglucose (FDG) has any prognostic value in patients with high-grade gliomas (III and IV), regardless of the treatment given.
Clinical Material and Methods
This series includes 45 consecutive patients with proven high-grade astrocytomas (Grades III and IV). Thirty-three patients were men (aged 24 to 68 years, mean 43.6 years) and 12 were women (aged 18 to 69 years, mean 41.6 years). Most of the patients had been treated elsewhere prior to their admission to our institution and were referred to us for further evaluation. Forty-two of them had undergone partial resection of the tumor, two had only a needle biopsy performed, and the diagnosis of malignancy was made from a cytological study of the cerebrospinal fluid in one. Besides surgery, all patients had received radiation therapy and, in addition, 32 patients had either completed or were receiving a course of chemotherapy during their hospitalization. When admitted to our institution all 45 patients were examined with contrast-enhanced CT scanning, which showed either residual tumor or recurrence of a previously treated tumor. Twenty-one of these tumors were located in the left hemisphere, and 16 were in the right hemisphere; in eight cases the tumor involved both hemispheres. Nineteen of the gliomas were frontal; l0 were parietal (some with extension into the occipital lobe); 11 were temporal; and four were deep-seated tumors. One tumor was located in the left cerebellum ( Table 1) .
The PET scans were performed in a controlled environment with the patients' eyes closed and the ears plugged to eliminate or diminish external sensory stimuli. Three to 5 mCi of FDG was injected in a peripheral vein of a hand. Both hands were warmed to facilitate arteriovenous shunting, and arterial blood samples were obtained at intervals from the time of injection to the time of completion of the scan. Approximately 30 to 40 minutes after injection, seven to 10 tomographic scans were obtained with the ECAT II scanner, and seven to 21 cuts were taken with the multislice Neuro-PET scanner,* as described by Sank, et alfl 8
The PET images were analyzed using the region of interest program of these instruments. The regional rate of glucose utilization was then calculated in the tumor area using a modification of the original Sokoloft formula. 3 Due to variability in local cerebral glucose utilization from patient to patient, the measured glucose utilization of the tumor was normalized by comparing it to the values of the opposite normal brain parenchyma. Thus, a glucose utilization ratio (tumor side: nontumor side) was used in the analysis of our data. The association between survival and this ratio as well as other variables was evaluated by Cox's nonparametric proportional hazards regression model? This method takes into consideration the fact that some patients are still alive. The relationship between the glucose utilization ratio and survival is graphically represented using the life-table method of Kaplan and Meier. Is
Results
The CT scans revealed the location of the tumor and various morphological characteristics, such as its configuration, the presence of central necrosis, and, on rare occasions, calcifications related to previous radiation treatment. In addition, on the CT scans after administration of contrast material, enhancement was present in the great majority of cases. Three tumors, which were isodense with the surrounding parenchyma on the plain scans, and one other, which was hypodense, failed to demonstrate enhancement. Edema of varying degree was invariably present around every tumor. These CT findings were equally common in both Grade III and Grade IV gliomas. Also, there were no CT features that could be used consistently to distinguish the very aggressive tumors, which led to a rapid demise of the patient, from the less aggressive tumors, which allowed survival for many months (Figs. 1 left pair and 2 left).
On the PET scans, the tumor was recognized in every case (Figs. 1 right pair and 2 right). In 36 patients, the rate of glucose utilization was higher in the tumor side than in the comparable region of the opposite hemisphere, for a glucose utilization ratio of greater than 1:1. In nine patients, although the tumor was recognized as an area of increased FDG uptake in a generally low activity region, the measured rate of glucose utilization was lower than that of the opposite hemisphere, and * ECAT II scanner manufactured by EG & G Ortec, Oak Ridge; Tennessee; multislice Neuro-PET scanner designed and fabricated at the National Institutes of Health. therefore the glucose utilization ratio was less than 1:1. When the glucose utilization ratios were plotted against the duration of survival, it was found that most patients with a high ratio died within a few months from the time of PET, whereas others with low ratios lived much longer, with some patients still alive as long as 32 months after the PET scanning. The median ratio for the 45 patients was 1.4:1. Patients with ratios equal to or less than 1.4:1 had a median survival time of 19 months, whereas patients with ratios greater than 1.4:1 had a median survival time of only 5 months. Figure 3 left shows the survival time distributions for the 45 N. J. Patronas, et al.
patients, based upon whether their glucose utilization ratio was above or below the median of 1.4:1. The association between this ratio and duration of survival was highly statistically significant (p < 0.001), as evaluated by Cox's nonparametric proportional hazards model without regard to arbitrary cutoff values. Figure 3 center shows that the tumor's histological grade (III versus IV) is also a prognostic factor for these patients (p < 0.005). It can be seen in Fig. 3 right, however, that the glucose utilization ratio is more important than histological grade for determining the duration of survival. Patients with ratios greater than 1.4:1 have very short survival times, regardless of whether the tumor is Grade III or IV. Patients with ratios less than 1.4:1 survive for longer. For the latter group of patients, tumor grade also seems to influence survival. Glucose utilization ratio is significantly (p < 0.05) related to survival times separately among patients with Grade III and Grade IV tumors. 0.005), as well as in cases of thalamic and hypothalamic neoplasms (p < 0.05). The survival times of patients with temporal tumors did not appear to differ based upon glucose utilization ratio.
The four patients whose tumors did not demonstrate enhancement on CT scan survived for 5, 13+, 18+, and 24+ months. This is not significantly different from the survival times of patients whose tumors demonstrated enhancement. The very small number of patients whose tumors did not enhance on CT scan limits the statistical significance of this factor, but it also indicates that absence of enhancement is not a very useful prognostic factor for patients with Grade III and IV tumors.
Discussion
Several factors influence the length of survival of patients with cerebral astrocytomas. The most obvious is the histological grade of the tumor, for it is well known that the length of survival of patients with Grade III and IV gliomas is considerably shorter than that of patients with gliomas of low grade (I or II). 32 Some clinical criteria have also been found to have prognostic value. Patients of younger age are more likely than older patients to attain long-term survival. The presenting symptoms are thought to be important, since it has been shown that patients who present with seizures or cranial nerve involvement have a more favorable prognosis than others, such as those with paralytic findings. In addition, the location of the tumor is known to have prognostic value, with deep-seated tumors and tumors in the parietal lobes having worse prognosis than tumors in the frontal or occipital regions. 13 There is evidence that the kind of treatment influ- Grade IV astrocytomas and a GU ratio > 1.4:1. Patients with GU ratios > 1.4:1 have very short survival times regardless of whether the tumor is GradeIII or IV. Thus, the GU ratio is a stronger prognostic factor than histological grading in these tumors. ences the length of survival. Among operative approaches, patients having only a biopsy have a shorter survival than those treated with resection, ~3 and it has recently been reported that the postoperative residual tumor burden is inversely related to the length of survival. 2 Radiation treatment following surgery is known to prolong useful life in patients with cerebral gliomas. Leibel, et aL, ~8 have shown that the 5-year survival rate for patients with resection alone is 17% compared to 46% in cases of resected and irradiated tumors.
Neuroradiological criteria of tumor aggressiveness have been described in numerous reports. During the era of angiography, it became obvious that cerebral astrocytomas which demonstrate tumor vessels, contrast medium stain, and early venous filling were malignant tumors and carried a poor prognosis. These features, however, are not necessarily indicators of an unfavorable outcome, since it is not uncommon to find angiographically avascular tumors that are subsequently proven to be high-grade gliomas. 37 With the advent of CT, several authors have used this method to characterize cerebral gliomas and to identify new prognostic factors determining the clinical outcome of these lesions. From the various published reports, the original high expectations appear to be only partly justified, and the results of these studies often seem contradictory. Thus, Levin, et al., ~9 found that patients with large contrast-enhancing tumors had a worse prognosis than did patients with smaller contrast-enhanced tumors. On the other hand, Reeves and Marks 27 found no correlation between lesion size and prognosis in glioblastomas. Tchang and co-workers 3~ found that the degree of enhancement of the tumor after intravenous injection of contrast material correlates linearly with the tumor grade. The usefulness of this information, however, is challenged by others who found that about 40% of low-grade gliomas demonstrate contrast enhancement. 23 Silverman and Marks, 29 reviewing 22 cases with low-grade astrocytomas, found that contrast enhancement had no prognostic significance in their patients.
Scanning with PET-FDG is a newer technique that measures the rate of glucose utilization by the tumor. Using this method, we have previously shown that there is a positive correlation between the histological grade of the tumor and rate of glucose utilization. 9 Thus, we have been able to separate Grade I and II from Grade III and IV gliomas. In the present study, we have included only the most aggressive types of gliomas (Grade III and IV). These tumors, although all malignant, do not progress or grow at the same rate. Their biological behavior varies and their response to treatment is also different from patient to patient.
Malignant tumors display a bias toward anaerobic metabolism, with a progressive increase in anaerobic glycolysis correlated to the grade of neoplasm. This consistent observation has been made both for tumors located outside the central nervous system 11,21,33-36 and for animal and human glioma tissue. 1'7'12"14'16'22'26'31'3~" Considering the relative inefficiency of the nonoxidative pathway, it is reasonable to assume that glucose utilization is higher in rapidly growing tumors, such as Grade III and IV astrocytomas, as compared to the less aggressive low-grade neoplasms, which tend to have a more favorable prognosis. In vivo confirmation of this assumption has been reported in previous publications, 7-~~ and is reinforced by this study in which we have demonstrated a strong inverse statistical correlation between deoxyglucose trapping by the tumor and the length of survival. This significant correlation holds both in patients with Grade Ill and in those with Grade IV gliomas, and is equally valid for patients with frontal, parietal, or thalamic tumors, but less valid for neoplasms in the temporal lobes. Possibly, the relatively frequent compression of the brain stem by temporal neoplasms worsens the prognosis, regardless of the glucose utilization ratio.
In conclusion, we believe that PET scan findings with FDG have prognostic value for high-grade gliomas and, in this respect, the PET-FDG technique is superior to CT or angiography. In addition, the PET-FDG grading of high-grade astrocytomas appears to be a more valuable prognostic criterion than the histological typing (Grade III versus IV). Finally, PET scans with FDG may be used to monitor the short-term tumor response to a given treatment.
